Vimarsana
Biggest News Aggregation in the World

Page 6 - Ryan Weispfenning News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ryan Weispfenning. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ryan Weispfenning Today - Breaking & Trending Today

Medtronic announces cash dividend for third quarter of fiscal year 2024 - Vimarsana News

Medtronic announces cash dividend for third quarter of fiscal year 2024

/PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, December 7, 2023, approved the company's cash dividend for the third quarter of...

Medtronic plc (NYSE:MDT) Q4 2024 Earnings Call Transcript - Vimarsana News

Medtronic plc (NYSE:MDT) Q4 2024 Earnings Call Transcript

Medtronic plc (NYSE:MDT) Q4 2024 Earnings Call Transcript November 21, 2023 Medtronic plc beats earnings expectations. Reported EPS is $1.25, expectations were $1.18. Ryan Weispfenning: Good morning. Welcome to a crisp fall morning here in Minnesota. I’m Ryan Weispfenning, Vice President and Head of Medtronic Investor Relations. And I appreciate that you’re joining us this […]

Source: yahoo.com
Medtronic reports second quarter fiscal 2024 financial results - Vimarsana News

Medtronic reports second quarter fiscal 2024 financial results

/PRNewswire/ -- Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key...

Medtronic (MDT) Q2 2024 Earnings Call Transcript - Vimarsana News

Medtronic (MDT) Q2 2024 Earnings Call Transcript

MDT earnings call for the period ending September 30, 2023.

Source: fool.com
Medtronic announces FDA approval of minimally invasive device to treat hypertension - Vimarsana News

Medtronic announces FDA approval of minimally invasive device to treat hypertension

The Symplicity™ blood pressure procedure offers patients a new adjunct approach to lowering blood pressure Approval is the culmination of ten years of clinical research and development of the...